Degenerative Disc Disease Market to Observe Stupendous Growth at ~19% CAGR by 2036, Due to Launch of Novel Drug Classes Such as Cell Replacement, NF-kappa B Inhibitors, Cartilage Regeneration via TGF-β1 Expression, and Others | DelveInsight

Summary

The degenerative disc disease market is shifting toward regenerative and disease-modifying therapies with emerging pipeline candidates such as SB-01 from Spine Biopharma and IDCT from DiscGenics, expected to drive ~19% CAGR growth through 2036.